Cell therapies could be the magic bullet for treating many different and previously intractable diseases. However creating a new cell therapy is fraught with complexities – sourcing, growing, transporting cells and other components for these therapies can be difficult. This event in partnership with the Medical Technologies Innovation Facility (MTIF) brings together speakers from charity, industry and academic sectors to provide considered insights into the different stages of cell therapy development from bench to bedside.
The webinar will address:
• The sustainable and ethical sourcing of human adult derived biological products as starting materials and criteria to consider when selecting the correct starting materials.
• Translating cell therapy into an implantable medical device with the adoption of substrates and scaffolds.
• Understanding cellular interactions with substrates and hence need to evaluate in-vitro biocompatibility.
• Reproducible and robust high throughput in-vitro testing for cell therapy performance validation.
There will be an opportunity to ask questions of our presenters in a Q&A session post presentation.
This webinar is open to all organisations seeking insight into cell therapy and the practicalities of development for patient use.
This free to attend event is held as part of the INSTILS programme – a project part-funded by the European Regional Development Fund, click here to be re-directed to further information about the project. This event is classed as State Aid to participating businesses, the value of which is £190, but is delivered completely free of charge to participants.
Speaker Profiles
Mike Hannay, Managing Director, Medical Technologies Innovation Facility (MTIF)
(CHAIR)
Professor John Hunt, Medical Technologies Innovation Facility (MTIF)
Katie Griffee, Business Development Manager, Anthony Noaln Cell & Gene Therapy Services
Katie supports cell and gene therapy researchers and developers access a scalable source of cellular starting material for R&D through to clinical application. Katie has a BSc in Biomedical Sciences and 7+ years’ experience working with pharmaceutical and biotech companies across Europe and the US.
Emma King, Sales Engineer, Hamamatsu Photonics UK Limited
Presentation: High Throughput Screening (HTS) of stem cells using the Hamamatsu FDSSµcell
Emma King studied Anatomy, Developmental and Human Biology at Kings College London, writing her thesis on cancer cell migration.
As part of the Research and Life Science group at Hamamatsu Photonics, Emma is responsible for business development activities for Functional Drug Screening Systems (FDSS) in the UK.
Ann Kramer, CEO, The Electrospinning Company
Ann Kramer is CEO of The Electrospinning Company, an SME with a biomaterial platform with applications in regenerative medicine and cell therapy. Ann spent 20 years in agritech multinationals, then 15 years in UK SMEs including Oxitec, Immunocore and Biosyntha.
